Chloroquine

Evidence Level: L5

Predicted Indications: 4

Chloroquine
Chloroquine: From Antimalarial Use to Rheumatoid Factor-Positive Polyarticular Juvenile Idiopathic Arthritis

## Pharmacist Assessment Report

Chloroquine: From Antimalarial Use to Rheumatoid Factor-Positive Polyarticular Juvenile Idiopathic Arthritis

One-Sentence Summary

Chloroquine is a long-established antimalarial drug (general pharmacological knowledge; the Evidence Pack contains no label indication text). The TxGNN model predicts it may be effective for rheumatoid factor-positive polyarticular juvenile idiopathic arthritis (JIA), but this specific prediction has 0 clinical trials and only 2 publications, and neither publication tests chloroquine directly.

Quick Overview

Item	Content
Original Indication	Antimalarial (label indication text not provided in the Evidence Pack)
Predicted New Indication	Rheumatoid factor-positive polyarticular juvenile idiopathic arthritis
TxGNN Prediction Score	99.41%
Evidence Level	L5
US Market Status	✓ Marketed
Number of NDAs	19
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Based on known information, chloroquine is an antimalarial (4-aminoquinoline) drug. Antimalarials are used more broadly as immunomodulatory agents in rheumatic disease, so it may be mechanistically applicable to juvenile arthritis. The Evidence Pack does not document this link, so it remains a hypothesis.

The TxGNN score (0.994) is a knowledge-graph prediction only. No chloroquine-specific mechanism, similarity analysis, or route-compatibility assessment is available.

Two related predicted indications have more direct drug-specific history. Juvenile chronic polyarthritis includes a small randomized comparison of chloroquine (Delagil) versus sulphasalazine (PMID 1688268). Juvenile idiopathic arthritis includes a 1974 chloroquine/hydroxychloroquine dosing study (PMID 4848261). Both are old, small, and low-tier evidence.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
24334641	2014	Cohort	J Rheumatol	Long-term real-life experience with leflunomide in JIA. This is not a chloroquine study, so it is background only.
8627446	1996	Case series	J Pediatr	Two RF-positive polyarticular JRA patients developed accelerated nodulosis on methotrexate. In one, nodules were arrested after adding hydroxychloroquine (a related drug, not chloroquine).

US Market Information

Authorization Number	Product Name	Dosage Form	Approved Indication
ANDA040516	Chloroquine Phosphate (Amneal Pharmaceuticals of New York LLC)	Tablet	Not listed in the Evidence Pack
ANDA040516	Chloroquine Phosphate (AvKARE)	Tablet	Not listed in the Evidence Pack
ANDA214756	Chloroquine Phosphate (Suven Pharmaceuticals Limited)	Tablet, coated	Not listed in the Evidence Pack
No number assigned	Chloroquinum Phos. (Hahnemann Laboratories, INC.)	Pellet	Not listed in the Evidence Pack

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction has no registered clinical trials, and its two publications do not test chloroquine directly. Evidence is at the model-prediction level (L5), and the package insert and mechanism data are missing.

To proceed, the following is needed:

FDA package insert warnings and contraindications, which are currently a blocking gap for safety screening
Chloroquine mechanism of action data, for example via the DrugBank API
Chloroquine-specific clinical evidence in JIA. Start with the related indications above (PMIDs 1688268 and 4848261) and separate chloroquine data from hydroxychloroquine data.
A decision on which JIA subtype to prioritize, since the related, better-documented predictions may be a stronger starting point than this RF-positive polyarticular subtype
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.